Orals Sessions WS06 Hot off the press: new data from drug trials| Volume 18, SUPPLEMENT 1, S11, June 01, 2019

WS06-3 Administration of ELX-02 to healthy volunteers demonstrates dose-linearity and proportionality as well as low inter-subject variability

DOI:https://doi.org/10.1016/S1569-1993(19)30150-X
WS06-3 Administration of ELX-02 to healthy volunteers demonstrates dose-linearity and proportionality as well as low inter-subject variability
Previous ArticleWS06-2 Initial results evaluating the add-on effect of the novel CFTR corrector PTI-801 in cystic fibrosis subjects
Next ArticleWS06-4 Ivacaftor (IVA) treatment in patients 6 to
      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment
      Purchase one-time access
      Subscribe to Journal of Cystic Fibrosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      Article Info

      Identification

      DOI: https://doi.org/10.1016/S1569-1993(19)30150-X

      Copyright

      © 2019 European Cystic Fibrosis Society. All rights reserved. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the Use of Cookies.
      Copyright © 2021 Elsevier Inc. except certain content provided by third parties.


      RELX